BDgene (Shanghai BDgene Therapeutics Co., Ltd.) focuses on innovative biopharmaceutical technologies aimed at developing advanced therapies for various diseases. The company specializes in gene editing and gene therapy, utilizing cutting-edge techniques to modify genetic material for therapeutic purposes. Their pipeline includes a range of products that target genetic disorders and cancers, leveraging their proprietary technologies to enhance the precision and efficacy of treatments. BDgene's commitment to research and development is evident in their efforts to create safe and effective solutions that address unmet medical needs.

In addition to gene editing, BDgene employs advanced delivery systems to ensure that therapeutic agents reach their intended targets within the body. This includes the use of nanoparticles and viral vectors, which facilitate the efficient transport of genetic material into cells. The company emphasizes the importance of safety and efficacy in their technologies, conducting rigorous preclinical and clinical studies to validate their approaches. By integrating these innovative technologies, BDgene aims to revolutionize the treatment landscape for patients suffering from genetic and oncological conditions.

China

Shanghai BDgene Therapeutics Co., Ltd. was established in 2018. The founder team includes top scientists in the field of gene therapy, industrial experts with a background in international pharmaceutical companies,  toxicology and safety pharmacology experts with preclinical drug evaluation experience.

BDgene (Shanghai BDgene Therapeutics Co., Ltd.)

Company Details